NCT06997068View on ClinicalTrials.gov

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 9, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Metastatic Oral Cavity CarcinomaRecurrent Oral Cavity CarcinomaStage IVC Lip and Oral Cavity Cancer AJCC v8
Interventions
DRUG

Celecoxib

Given PO

DRUG

Erlotinib Hydrochloride

Given PO

PROCEDURE

Imaging Procedure

Undergo SOC imaging scans

OTHER

Interview

Ancillary studies

DRUG

Methotrexate

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06997068 - Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population | Biotech Hunter | Biotech Hunter